Mixed Results With RT Plus Short-Term ADT in Intermediate-Risk Prostate Cancer
CHICAGO — Adding a short course of androgen deprivation therapy (ADT) to dose-escalated radiotherapy (RT) led to a mixed bag of outcomes in intermediate-risk prostate cancer, according to a large randomized trial. The addition of 6 months of ADT did not improve overall survival (OS) compared with RT alone, but the hormonal therapy was associated […]
Meta-Analysis Reaffirms Role of ADT With Radiotherapy in Prostate Cancer
CHICAGO — The use of androgen deprivation therapy (ADT) in conjunction with radiotherapy, as well as its prolonged use in the adjuvant setting, improved metastasis-free survival (MFS) and overall survival (OS) in patients with localized prostate cancer, a meta-analysis found. Adding ADT to radiotherapy significantly improved 12-year rates of MFS, the primary endpoint (HR 0.83, […]
ADT Options for Prostate Cancer Come Out Even for Heart Safety
Androgen deprivation therapy (ADT) options for prostate cancer seemed to have a similar impact on the risk of cardiovascular events among people with documented heart disease, according to results from the PRONOUNCE trial, although the study was terminated early due to slow accrual. In 545 men, there was no statistically significant difference in the rate […]
When Is ADT Right for Biochemically Recurrent Prostate Cancer?
Men with prostate cancer and biochemical recurrence (BCR) who delayed androgen deprivation therapy (ADT) still experienced long survival outcomes, researchers reported. In a retrospective study, men with a prostate-specific antigen doubling time (PSADT) of less than 10 months saw a median metastases-free survival (MFS) of 192 months when they delayed ADT until metastasis, and a […]
Could Docetaxel Have Role in Unfavorable-Risk Prostate Cancer?
Adding docetaxel to androgen deprivation therapy (ADT) plus radiation therapy (RT) failed to improve survival in unfavorable-risk prostate cancer, though the combination may hold benefit for certain patients, long-term results of a randomized trial found. While the regimen did not prolong overall survival (OS) among all men with unfavorable-risk nonmetastatic cancer after a median of […]